Daxor Corporation said it opened a new Blood Volume Analysis (BVA) diagnostic program at a leading healthcare facility in Southern Middle Tennessee as part of its expansion into the outpatient cardiology market. The company said the site will use Daxor’s Tennessee-based ezBVA Lab workflow, providing a 24-hour turnaround time for comprehensive blood volume metrics, and cited 98% diagnostic accuracy. Daxor also said the ezBVA Lab service enables outpatient adoption with reimbursement codes and no capital investment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daxor Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240800PRIMZONEFULLFEED9659820) on February 24, 2026, and is solely responsible for the information contained therein.

